Literature DB >> 8544958

In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment.

H E Möller1, P Vermathen, K Ullrich, J Weglage, H G Koch, P E Peters.   

Abstract

Localized proton magnetic resonance spectroscopy at short echo times was used to measure phenylalanine (Phe) in parieto-occipital periventricular brain. Six treated adult patients with phenylketonuria were investigated repeatedly following reinstitution of a Phe-restricted diet. Difference spectroscopy clearly enabled the identification of elevated cerebral Phe levels by subtracting spectra obtained from healthy volunteers. Estimates of absolute brain concentrations always yielded values well below the serum levels with ratios [Phe]brain/[Phe]serum ranging from 0.27 to 0.63. A plot of [Phe]brain versus [Phe]serum could be fitted to a straight line (R = 0.90) if [Phe]serum was below 1.3 mM. Measurements at higher serum levels could only be performed in one patient and yielded brain Phe concentrations of 0.63 +/- 0.10 mM suggesting a saturation of the carrier systems. The feasibility to quantify Phe transport across the blood-brain barrier in humans non-invasively employing in-vivo proton spectroscopy can effectively improve the prognostic significance of serum data.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8544958     DOI: 10.1055/s-2007-979753

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  7 in total

1.  Decreasing choline signal--a marker of phenylketonuria?

Authors:  M Dezortová; L Hejcmanová; M Hájek
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

2.  Brain phenylalanine concentration in the management of adults with phenylketonuria.

Authors:  R A Moats; R Koch; K Moseley; P Guldberg; F Guttler; R G Boles; M D Nelson
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy.

Authors:  C S Zuo; P V Prasad; P Busse; L Tang; R G Zamenhof
Journal:  Med Phys       Date:  1999-07       Impact factor: 4.071

4.  Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis.

Authors:  Martijn J de Groot; Paul E Sijens; Dirk-Jan Reijngoud; Anne M Paans; Francjan J van Spronsen
Journal:  J Cereb Blood Flow Metab       Date:  2014-10-29       Impact factor: 6.200

5.  Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.

Authors:  J Weglage; D Wiedermann; J Denecke; R Feldmann; H G Koch; K Ullrich; H E Möller
Journal:  J Inherit Metab Dis       Date:  2002-10       Impact factor: 4.982

6.  Phenylalanine can be detected in brain tissue of healthy subjects by 1H magnetic resonance spectroscopy.

Authors:  J Pietz; T Lutz; K Zwygart; G F Hoffmann; F Ebinger; C Boesch; R Kreis
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

7.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.